title: Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin).
abstract: Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in which the patients suffered from intestinal perforation after chemotherapy with bevacizumab. For the first case, a 47 year-old man had rectal cancer with concurrent liver and lung metastasis. He underwent chemotherapy with 5-fluorouracil, irinotecan and bevacizumab. Fever and abdominal pain developed seven days later, and rectal perforation was identified upon exploration 13 days later. For the second case, a 48 year-old woman had sigmoid colon cancer with peritoneal and ovary metastases. After seven days of chemotherapy with 5-fluorouracil, oxaliplatin and bevacizumab, exploratory surgery revealed a perforation at the ileum.
authors.affiliation: Department of Surgery, Kosin University College of Medicine, Busan, Korea.
authors.forename: Young Il
authors.initials: YI
authors.lastname: Choi
authors.forename: Seung Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Byung Kwon
authors.initials: BK
authors.lastname: Ahn
authors.forename: Sung Uhn
authors.initials: SU
authors.lastname: Baek
authors.forename: Seun Ja
authors.initials: SJ
authors.lastname: Park
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Kim
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Shin
references.citation: Gynecol Oncol. 2007 Apr;105(1):3-6
references.pmid: 17383545
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1295-8
references.pmid: 16503384
references.citation: J Surg Oncol. 2005 Sep 1;91(3):173-80
references.pmid: 16118771
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: J Clin Oncol. 2003 Jan 1;21(1):60-5
references.pmid: 12506171
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3354-60
references.pmid: 16849749
references.citation: Oncology. 2005;69 Suppl 3:25-33
references.pmid: 16301833
references.citation: Curr Surg. 2006 Sep-Oct;63(5):334-7
references.pmid: 16971205
references.citation: Ann Surg Oncol. 2007 Jun;14(6):1860-9
references.pmid: 17356952